Furthermore, studies in animals [74] have demonstrated that naringenin mitigates non-alcoholic fatty liver disease by down-regulating the NLRP3/NF-κB pathway in mice. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatotic liver disease.